Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Ramtin Pourahmad¹, Bobak Moazzami^{1

2}, Nima Rezaei^{1

2}

Affiliations

¹ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
² Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 32838178
PMCID: PMC7392618
DOI: 10.1007/s42399-020-00438-2

Review

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Ramtin Pourahmad et al. SN Compr Clin Med. 2020.

. 2020;2(9):1407-1411.

doi: 10.1007/s42399-020-00438-2. Epub 2020 Jul 31.

Authors

Ramtin Pourahmad¹, Bobak Moazzami^{1

2}, Nima Rezaei^{1

2}

Affiliations

¹ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
² Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 32838178
PMCID: PMC7392618
DOI: 10.1007/s42399-020-00438-2

Abstract

Since the rapidly evolving outbreak of COVID-19, several empirical therapeutic options have been recommended including the use of antivirals, steroids, and vaccines. According to recent observations about different modalities in treatment of patients infected with COVID-19, plasmapheresis and intravenous immunoglobulin (IVIg) have been reported to be an effective empirical therapeutic option to control the infection. In this review, we aimed to provide an overview on the possible application of plasmapheresis and intravenous immunoglobulin in patients with COVID-19.

Keywords: COVID-19; Coronavirus; Intravenous immunoglobulin; Plasmapheresis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare that they have no conflict of interest.

Cited by

COVID-19: The experience from Iran.
Daneshpazhooh M, Mahmoudi H. Daneshpazhooh M, et al. Clin Dermatol. 2021 Jan-Feb;39(1):23-32. doi: 10.1016/j.clindermatol.2020.12.009. Epub 2020 Dec 15. Clin Dermatol. 2021. PMID: 33972048 Free PMC article.
Potential therapeutic approach of intravenous immunoglobulin against COVID-19.
Kolahchi Z, Sohrabi H, Ekrami Nasab S, Jelodari Mamaghani H, Keyfari Alamdari M, Rezaei N. Kolahchi Z, et al. Allergy Asthma Clin Immunol. 2021 Oct 9;17(1):105. doi: 10.1186/s13223-021-00609-3. Allergy Asthma Clin Immunol. 2021. PMID: 34627384 Free PMC article. Review.
Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial.
Gholinataj Jelodar M, Rafieian S, Saghafi F, Hadad Zedegan N, Birjandi B, Rafieian S, Allah Dini A, Dehghanpour H, Khalaj F, Zare S, Dehghan Chenari H, Hajimaghsoudi M, Mojtaba Sohrevardi S, Mirzaei S, Jamialahmadi T, Atkin SL, Sahebkar A. Gholinataj Jelodar M, et al. Int Immunopharmacol. 2023 Feb;115:109623. doi: 10.1016/j.intimp.2022.109623. Epub 2022 Dec 21. Int Immunopharmacol. 2023. PMID: 36577157 Free PMC article. Review.
Ofeleein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.
Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiridou-Chatzopoulou M, Papazoglou DD, Doulberis M. Kountouras J, et al. Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309. Medicina (Kaunas). 2022. PMID: 35208631 Free PMC article. Review.
Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
Mohamed K, Yazdanpanah N, Saghazadeh A, Rezaei N. Mohamed K, et al. Bioorg Chem. 2021 Jan;106:104490. doi: 10.1016/j.bioorg.2020.104490. Epub 2020 Nov 19. Bioorg Chem. 2021. PMID: 33261845 Free PMC article.

See all "Cited by" articles

References

1. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. - PMC - PubMed
1. Koch B, Schult-Dietrich P, Büttner S, Dilmaghani B, Lohmann D, Baer PC, Dietrich U, Geiger H. Lectin affinity plasmapheresis for Middle East respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination. Blood Purif. 2018;46(2):126–133. - PMC - PubMed
1. Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, Gai W, Zheng X, Wang T, Sun W, Yan F, Gao Y, Wang Q, Yan J, Chen L, Perlman S, Zhong N, Zhao J, Yang S, Xia X. Passive immunotherapy for Middle East respiratory syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antivir Res. 2017;137:125–130. - PMC - PubMed
1. Keith P, Day M, Choe C, Perkins L, Moyer L, Hays E, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE open medical case reports. 2020;8:2050313x20933473. - PMC - PubMed
1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582–1589. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Affiliations

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources